- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 381459, 10 pages
Botulinum Toxin for the Treatment of Myofascial Pain Syndromes Involving the Neck and Back: A Review from a Clinical Perspective
1Physical and Rehabilitation Medicine Department, Alicante University General Hospital, C/Pintor Baeza s/n, 03010 Alicante, Spain
2Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan
3Pain Clinic, La Fe Hospital, 46026 Valencia, Spain
4Physical and Rehabilitation Medicine Department, Gran Canaria Insular Hospital, Avenida Marítima del Sur, 35006 Las Palmas de Gran Canaria, Spain
Received 28 November 2012; Accepted 21 January 2013
Academic Editor: Chang-Zern Hong
Copyright © 2013 José M. Climent et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. G. Simons, “Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction,” Journal of Electromyography and Kinesiology, vol. 14, no. 1, pp. 95–107, 2004.
- K. A. Sluka, A. Kalra, and S. A. Moore, “Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia,” Muscle & Nerve, vol. 24, no. 1, pp. 37–46, 2001.
- R. D. Gerwin, J. Dommerholt, and J. P. Shah, “An expansion of Simons' integrated hypothesis of trigger point formation,” Current pain and headache reports, vol. 8, no. 6, pp. 468–475, 2004.
- T. S. Kuan, Y. C. Chang, and C. Z. Hong, “Distribution of active loci in rat skeletal muscle,” Journal of Musculoskeletal Pain, vol. 7, no. 4, pp. 45–54, 1999.
- C. Z. Hong, “New trends in myofascial pain syndrome,” Chinese Medical Journal, vol. 65, no. 11, pp. 501–512, 2002.
- D. G. Simons, C. Z. Hong, and L. S. Simons, “Endplate potentials are common to midfiber myofacial trigger points,” American Journal of Physical Medicine and Rehabilitation, vol. 81, no. 3, pp. 212–222, 2002.
- C. Z. Hong and D. G. Simons, “Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points,” Archives of Physical Medicine and Rehabilitation, vol. 79, no. 7, pp. 863–872, 1998.
- J. P. Shah, T. M. Phillips, J. V. Danoff, and L. H. Gerber, “An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle,” Journal of Applied Physiology, vol. 99, no. 5, pp. 1977–1984, 2005.
- J. P. Shah, J. V. Danoff, M. J. Desai et al., “Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 1, pp. 16–23, 2008.
- S. Mense, “Muscle pain: mechanisms and clinical significance,” Deutsches Arzteblatt, vol. 105, no. 12, pp. 214–219, 2008.
- L. R. Watkins, M. R. Hutchinson, A. Ledeboer, J. Wieseler-Frank, E. D. Milligan, and S. F. Maier, “Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids,” Brain, Behavior, and Immunity, vol. 21, no. 2, pp. 131–146, 2007.
- M. F. Brin, “Botulinum toxin: chemistry, pharmacology, toxicity, and immunology,” Muscle and Nerve, vol. 20, supplement 6, pp. S146–S168, 1997.
- J. Costa, C. Espírito-Santo, A. Borges et al., “Botulinum toxin type A therapy for cervical dystonia,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003633, 2005.
- J. O. Dolly and K. R. Aoki, “The structure and mode of action of different botulinum toxins,” European Journal of Neurology, vol. 13, supplement 4, pp. 1–9, 2006.
- D. B. Lacy and R. C. Stevens, “Sequence homology and structural analysis of the clostridial neurotoxins,” Journal of Molecular Biology, vol. 291, no. 5, pp. 1091–1104, 1999.
- Y. Aikawa, K. L. Lynch, K. L. Boswell, and T. F. J. Martin, “A second SNARE role for exocytic SNAP25 in endosome fusion,” Molecular Biology of the Cell, vol. 17, no. 5, pp. 2113–2124, 2006.
- L. L. Simpson, A. B. Maksymowych, and S. Hao, “The role of zinc binding in the biological activity of botulinum toxin,” The Journal of Biological Chemistry, vol. 276, no. 29, pp. 27034–27041, 2001.
- A. T. Brunger and A. Rummel, “Receptor and substrate interactions of clostridial neurotoxins,” Toxicon, vol. 54, no. 5, pp. 550–560, 2009.
- S. Mense, “Neurobiological basis for the use of botulinum toxin in pain therapy,” Journal of Neurology, Supplement, vol. 251, supplement 1, pp. I1–I7, 2004.
- T. S. Kuan, J. T. Chen, S. M. Chen, C. H. Chien, and C. Z. Hong, “Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle,” American Journal of Physical Medicine and Rehabilitation, vol. 81, no. 7, pp. 512–520, 2002.
- K. R. Aoki, “Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A,” NeuroToxicology, vol. 26, no. 5, pp. 785–793, 2005.
- B. Jabbari, “Botulinum neurotoxins in the treatment of refractory pain,” Nature Clinical Practice Neurology, vol. 4, no. 12, pp. 676–685, 2008.
- K. R. Aoki and J. Francis, “Updates on the antinociceptive mechanism hypothesis of botulinum toxin A,” Parkinsonism and Related Disorders, vol. 17, supplement 1, pp. S28–S33, 2011.
- P. Gazerani, C. Staahl, A. M. Drewes, and L. Arendt-Nielsen, “The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization,” Pain, vol. 122, no. 3, pp. 315–325, 2006.
- W. P. Cheshire, S. W. Abashian, and J. D. Mann, “Botulinum toxin in the treatment of myofascial pain syndrome,” Pain, vol. 59, no. 1, pp. 65–69, 1994.
- M. Ernberg, B. Hedenberg-Magnusson, T. List, and P. Svensson, “Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study,” Pain, vol. 152, no. 9, pp. 1988–1996, 2011.
- J. De Andrés, V. M. Adsuara, S. Palmisani, V. Villanueva, and M. D. López-Alarcón, “A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans,” Regional Anesthesia and Pain Medicine, vol. 35, no. 3, pp. 255–260, 2010.
- K. Gül and A. S. Onal, “Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome,” Agri, vol. 21, no. 3, pp. 104–112, 2009.
- R. A. De Venancio, F. G. P. Alencar, and C. Zamperini, “Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches,” Cranio, vol. 27, no. 1, pp. 46–53, 2009.
- R. N. Harden, J. Cottrill, C. M. Gagnon et al., “Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study,” Headache, vol. 49, no. 5, pp. 732–743, 2009.
- C. Braker, S. Yariv, R. Adler, S. Badarny, and E. Eisenberg, “The analgesic effect of botulinum-toxin A on postwhiplash neck pain,” Clinical Journal of Pain, vol. 24, no. 1, pp. 5–10, 2008.
- H. L. Lew, E. H. Lee, A. Castaneda, R. Klima, and E. Date, “Therapeutic use of Botulinum Toxin Type A in treating neck and upper-back pain of Myofascial Origin: a pilot study,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 1, pp. 75–80, 2008.
- E. Qerama, A. Fuglsang-Frederiksen, H. Kasch, F. W. Bach, and T. S. Jensen, “A double-blind, controlled study of botulinum toxin A in chronic myofascial pain,” Neurology, vol. 67, no. 2, pp. 241–245, 2006.
- H. Göbel, A. Heinze, G. Reichel, H. Hefter, and R. Benecke, “Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study,” Pain, vol. 125, no. 1-2, pp. 82–88, 2006.
- T. Ojala, J. P. A. Arokoski, and J. Partanen, “The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial,” Clinical Journal of Pain, vol. 22, no. 1, pp. 90–96, 2006.
- C. L. Graboski, D. Shaun Gray, and R. S. Burnham, “Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study,” Pain, vol. 118, no. 1-2, pp. 170–175, 2005.
- F. M. Ferrante, L. Bearn, R. Rothrock, and L. King, “Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A,” Anesthesiology, vol. 103, no. 2, pp. 377–383, 2005.
- A. Kamanli, A. Kaya, O. Ardicoglu, S. Ozgocmen, F. O. Zengin, and Y. Bayik, “Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome,” Rheumatology International, vol. 25, no. 8, pp. 604–611, 2005.
- A. M. Lang, “Botulinum Toxin Type B in Piriformis Syndrome,” American Journal of Physical Medicine and Rehabilitation, vol. 83, no. 3, pp. 198–202, 2004.
- J. De Andrés, G. Cerda-Olmedo, J. C. Valía, V. Monsalve, Lopez-Alarcón, and A. Minguez, “Use of botulinum toxin in the treatment of chronic myofascial pain,” Clinical Journal of Pain, vol. 19, no. 4, pp. 269–275, 2003.
- L. Foster, L. Clapp, M. Erickson, and B. Jabbari, “Botulinum toxin A and chronic low back pain a randomized, double-blind study,” Neurology, vol. 56, no. 10, pp. 1290–1293, 2001.
- L. M. Fishman, C. Anderson, and B. Rosner, “BOTOX and physical therapy in the treatment of piriformis syndrome,” American Journal of Physical Medicine and Rehabilitation, vol. 81, no. 12, pp. 936–942, 2002.
- M. Porta, “A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm,” Pain, vol. 85, no. 1-2, pp. 101–105, 2000.
- A. H. Wheeler, P. Goolkasian, and S. S. Gretz, “A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome,” Spine, vol. 23, no. 15, pp. 1662–1667, 1998.
- R. Gerwin, “Botulinum toxin treatment of myofascial pain: a critical review of the literature,” Current Pain and Headache Reports, vol. 16, no. 5, pp. 413–422, 2012.
- A. Soares, R. B. Andriolo, A. N. Atallah, and E. M. K. Da Silva, “Botulinum toxin for myofascial pain syndromes in adults,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD007533, 2009.
- T. Zhang, A. Adatia, W. Zarin et al., “The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis,” Inflammopharmacology, vol. 19, no. 1, pp. 21–34, 2011.
- E. Qerama, A. Fuglsang-Frederiksen, and T. S. Jensen, “The role of botulinum toxin inmanagement of pain: an evidence-based review,” Current Opinion in Anesthesiology, vol. 23, no. 5, pp. 602–610, 2010.
- O. C. Colhado, M. Boeing, and L. B. Ortega, “Botulinum toxin in pain treatment,” Revista Brasileira de Anestesiologia, vol. 59, no. 3, pp. 366–381, 2009.
- K. Y. Ho and K. H. Tan, “Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review,” European Journal of Pain, vol. 11, no. 5, pp. 519–527, 2007.
- C. A. Pereda, J. Usón Jaeger, and L. Carmona, “Systematic review: can botulinum toxin be recommended as treatment for pain in myofascial syndrome?” Reumatologia Clinica, vol. 2, no. 4, pp. 173–182, 2006.
- P. Reilich, K. Fheodoroff, U. Kern et al., “Consensus statement: botulinum toxin in myofacial pain,” Journal of Neurology, vol. 251, supplement 1, pp. I36–I38, 2004.
- A. M. Lang, “Botulinum toxin type A therapy in chronic pain disorders,” Archives of Physical Medicine and Rehabilitation, vol. 84, no. 3, Supplement 1, pp. S69–S73, 2003.
- P. Langevin, P. M. Peloso, J. Lowcock et al., “Botulinum toxin for subacute/chronic neck pain,” Cochrane Database of Systematic Reviews, no. 7, Article ID CD008626, 2011.
- Z. Waseem, C. Boulias, A. Gordon, F. Ismail, G. Sheean, and A. D. Furlan, “Botulinum toxin injections for low-back pain and sciatica,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD008257, 2011.
- B. Jabbari and D. Machado, “Treatment of refractory pain with botulinum toxins-an evidence-based review,” Pain Medication, vol. 12, no. 11, pp. 1594–1606, 2011.
- M. Naumann, Y. So, C. E. Argoff et al., “Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,” Neurology, vol. 70, no. 19, pp. 1707–1714, 2008.
- N. A. Scott, B. Guo, P. M. Barton, and R. D. Gerwin, “Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review,” Pain Medicine, vol. 10, no. 1, pp. 54–69, 2009.
- J. J. Ferreira, M. Couto, J. Costa, M. Coelho, M. M. Rosa, and C. Sampaio, “Botulinum toxin for the treatment of pain syndromes,” Acta reumatológica portuguesa, vol. 31, no. 1, pp. 49–62, 2006.
- R. D. Gerwin, S. Shannon, C. Z. Hong, D. Hubbard, and R. Gevirtz, “Interrater reliability in myofascial trigger point examination,” Pain, vol. 69, no. 1-2, pp. 65–73, 1997.
- S. Sikdar, J. P. Shah, T. Gebreab et al., “Novel applications of ultrasound technology to visualize and characterize myofascial trigger points (MTrPs) and surrounding soft tissue,” Archives of Physical Medicine and Rehabilitation, vol. 90, pp. 1829–1838, 2009.
- E. A. Tough, A. R. White, S. Richards, and J. Campbell, “Variability of criteria used to diagnose myofascial trigger point pain syndrome—evidence from a review of the literature,” Clinical Journal of Pain, vol. 23, no. 3, pp. 278–286, 2007.
- C. R. Hou, L. C. Tsai, K. F. Cheng, K. C. Chung, and C. Z. Hong, “Immediate effects of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity,” Archives of Physical Medicine and Rehabilitation, vol. 83, no. 10, pp. 1406–1414, 2002.
- R. D. Gerwin, “Classification, epidemiology, and natural history of myofascial pain syndrome,” Current Pain and Headache Reports, vol. 5, no. 5, pp. 412–420, 2001.
- B. J. Freund and M. Schwartz, “Erratum: Treatment of whiplash associated with neck pain with botulinum toxin-A: a pilot study,” Journal of Rheumatology, vol. 27, no. 6, p. 1577, 2000.
- H. Shankar and C. Cummings, “Ultrasound imaging of embedded shrapnel facilitates diagnosis and management of myofascial pain syndrome,” Pain Practice, 2012.
- B. Jabbari, J. Ney, A. Sichani, W. Monacci, L. Foster, and M. Difazio, “Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study,” Pain Medicine, vol. 7, no. 3, pp. 260–264, 2006.
- C. Z. Hong, “Lidocaine injection versus dry needling to myofascial trigger point: the importance of the local twitch response,” American Journal of Physical Medicine and Rehabilitation, vol. 73, no. 4, pp. 256–263, 1994.
- S. H. Yoon, U. W. Rah, S. S. Sheen, and K. H. Cho, “Comparison of 3 needle sizes for trigger point injection in myofascial pain syndrome of upper- and middle-trapezius muscle: a randomized controlled trial,” Archives of Physical Medicine and Rehabilitation, vol. 90, no. 8, pp. 1332–1339, 2009.
- A. E. Sola and J. H. Kuitert, “Myofascial trigger point pain in the neck and shoulder girdle,” Northwest Medicine, vol. 54, pp. 980–984, 1955.
- A. E. Sola and R. L. Williams, “Myofascial pain syndromes,” Neurology, vol. 6, pp. 91–95, 1956.
- F. A. Frost, B. Jessen, and J. Siggaard-Andersen, “A control, double-blind comparison of mepivacaine injection versus saline injection for myofascial pain,” The Lancet, vol. 1, no. 8167, pp. 499–500, 1980.
- P. Tfelt Hansen, I. Lous, and J. Olesen, “Prevalence and significance of muscle tenderness during common migraine attacks,” Headache, vol. 21, no. 2, pp. 49–54, 1981.
- K. Lewit, “The needle effect in the relief of myofascial pain,” Pain, vol. 6, no. 1, pp. 83–90, 1979.
- P. Baldry, “Management of myofascial trigger point pain,” Acupuncture in Medicine, vol. 20, no. 1, pp. 2–10, 2002.
- D. Miller, D. Richardson, M. Eisa, R. J. Bajwa, and B. Jabbari, “Botulinum neurotoxin-a for treatment of refractory neck pain: a randomized, double-blind study,” Pain Medicine, vol. 10, no. 6, pp. 1012–1017, 2009.
- L. C. Jeynes and C. A. Gauci, “Evidence for the use of botulinum toxin in the chronic pain setting—a review of the literature,” Pain Practice, vol. 8, no. 4, pp. 269–276, 2008.